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ABSTRACT
BACKGROUND: Proinfl ammatory cytokines have been known to play a considerable part in the pathomech-
anisms of chronic heart failure (CHF). Given the importance of proinfl ammatory cytokines in the context 
of the failing heart, we assessed whether the polymorphisms of interleukin (IL)-1 gene cluster, including 
IL-1α, IL-1β, and IL-1 receptor antagonist (IL-1RA) and IL-1R gene are predictors of CHF due to ischemic 
heart disease.
METHODS: Forty- three patients with ischemic heart failure were recruited in this study as patients group and 
compared with 140 healthy unrelated control subjects. Using polymerase chain reaction with sequence-specifi c 
primers method, the allele and genotype frequency of 5 single nucleotide polymorphisms (SNPs) within the IL-
1α (-889), IL-1β (-511, +3962), IL-1R (psti 1970), and IL-1RA (mspa1 11100) genes were determined.
RESULTS: The frequency of the IL-1β -511/C allele was signifi cantly higher in the patient group compared to 
that in the control group (p = 0.031). The IL-1β (-511) C/C genotype was signifi cantly overrepresented in pa-
tients compared to controls (p = 0.022). 
CONCLUSIONS: Particular allele and genotype in IL-1β gene were overrepresented in patients with ischemic heart 
failure, possibly affecting the individual susceptibility to this disease (Tab. 1, Ref. 27). Text in PDF www.elis.sk.
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Introduction
Chronic heart failure (CHF) is a compelling public health 
problem characterized by depressed contractile function and pro-
gressive ventricular dila tion, with an incidence rate of 10 per 1000 
population after the age of 65 (1, 2). Given the increasing economic 
and social impact of the disease, it stands to reason that identifi ca-
tion of novel genetic markers, which affect individual susceptibil-
ity to the development of CHF, would be crucial for initiating the 
therapy at an early stage of the disease. 
Elevated intracardiac and circulatory levels of proinfl amma-
tory cytokines have been hitherto revealed in patients with CHF 
(3–5). These cytokines’ contribution towards the initiation and 
progression of the underlying cardiovascular diseases, especially 
coronary artery disease (CAD), have been a topic of intensive 
research recently (6, 7). Given the potential role of IL-1 in the 
infl ammation-triggered pathway of thrombus formation, and its 
importance in vulnerability to the ischemic arterial disease (8), 
IL-1 gene polymorphisms might infl uence the individual prone-
ness to ischemic heart failure (IHF).
It has been described that genetic polymorphisms within the 
coding and promoter regions of cytokine genes could regulate 
their production (9–11). Notwithstanding the fact that association 
of certain cytokines single nucleotide polymorphisms (SNPs) has 
been studied in a number of immunological diseases (12–21), our 
understanding in CHF is limited due to the paucity of investiga-
tions in this area. The role of polymorphisms in IL-1 gene cluster 
and IL-1 receptor gene in CHF has not been fully investigated 
and to the best of our knowledge, this is the fi rst study examining 
the possible contributions of SNPs in IL-1 family genes toward 
susceptibility to CHF in Iranian patients.
The primary objective of this study was to determine the asso-
ciations between certain IL-1 gene cluster and IL-1 receptor gene 
polymorphisms and CHF in a group of Iranian patients.
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Patients and methods
Subjects
Forty-three consecutive Iranian patients diagnosed with chron-
ic ischemic heart failure (mean age 60.05 ± 11.97; 34 men, 9 
women) with angiographically signifi cant CAD, defi ned as ≥ 50 
% diameter stenosis in at least one of the major coronary arter-
ies, were recruited in the current study. The diagnosis of chronic 
heart failure was made according to the presence of impaired left 
ventricular systolic function (left ventricular ejection fraction ≤ 
40 %) and left ventricular dilation (left ventricular end-diastolic 
diameter > 5.5 cm) on echocardiography. Subjects with malignan-
cies, acute decompensated heart failure within 3 months prior to 
recruitment, recent myocardial infarction, and chronic lung dis-
ease were excluded. Transthoracic echocardiography and cardiac 
catheterization were performed for all patients. Eligible patients 
were in stable clinical condition and received conventional medical 
therapy for at least 3 months. One hundred and forty healthy indi-
viduals (mean age 45.63 ± 10.84; 101 men, 39 women), who were 
randomly selected from blood donors at Iranian blood transfusion 
organizations, were enrolled as the control group (22). 
The study was approved by the Ethical Committee of Tehran 
University of Medical Sciences. Written informed consent was 
obtained from all participants before blood sampling.
Genotyping
An amount of 5 mL of peripheral blood was collected from all 
of the participants in this study and kept with ethylenediaminetet-
raacetic acid (EDTA) as anticoagulant, at –20 °C until investiga-
tion. Genomic DNA was extracted from peripheral blood leuko-
cytes using the “salting out” technique (23). Cytokine typing was 
performed using polymerase chain reaction with sequence-specifi c 
primers (PCR-SSP) assay (PCR-SSP kit, Heidelberg University, 
Heidelberg, Germany), as discussed previously (22). Amplifi cation 
of the isolated DNA was carried out using a thermal cycler Techne 
Flexigene apparatus (Rosche, Cambridge, UK) under the following 
conditions: initial denaturation at 94 °C for 2 min; denaturation 
at 94 °C for 10 sec; annealing + extension at 65 °C for 1 min (10 
cycles); denaturation at 94 °C for 10 sec; annealing at 61 °C for 
50 sec; extension at 72 °C for 30 sec (20 cycles). The presence or 
absence of polymerase chain reaction (PCR) products was visual-
ized by 2 % agarose gel electrophoresis and subsequent ultraviolet 
transilluminator. All individuals were genotyped for 5 polymorphic 
sites in 4 cytokine genes, namely: IL-1α, -889 T/C; IL-1β, -511 C/T 
and +3962 T/C; IL-1R, psti 1970 C/T; IL-1RA, mspa1 11100 T/C.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 
5.00 for Windows (Graphpad Software). Allele and genotype fre-
Cytokine Position Alleles/
Genotypes
Patients (n=43)
n (%)
Controls (n=140)
n (%)
p-value Odds ratio (95% CI)
 n = 42 N = 136
IL-1α -889 C
T
CC
CT
TT
59 (70.2)
25 (29.8)
20 (47.6)
19 (45.2)
3 (7.2)
186 (68.4)
86 (31.6)
62 (45.6)
62 (45.6)
12 (8.8)
0.789
0.789
0.860
1.000
1.000
1.09 (0.64 to 1.86)
0.92 (0.54 to 1.56)
1.09 (0.54 to 2.17)
0.99 (0.49 to 1.98)
0.79 (0.21 to 2.96)
N=42 N=139
IL-1ß -511 C
T
CC
TC
TT
58 (69)
26 (31)
19 (45.2)
20 (47.6)
3 (7.2)
154 (55.4)
124 (44.6)
36 (25.8)
82 (59)
21 (15.2)
0.031
0.031
0.022
0.217
0.297
1.8 (1.07 to 3.02)
0.56 (0.33 to 0.94)
2.37 (1.15 to 4.84)
0.63 (0.32 to 1.27)
0.43 (0.12 to 1.53)
N=41 N=140
IL-1ß +3962 C
T
CC
TC
TT
60 (73)
22 (27)
21 (51.2)
18 (44)
2 (4.8)
198 (70.7)
82 (29.3)
70 (50)
58 (41.4)
12 (8.6)
0.782
0.782
1.000
0.858
0.739
1.13 (0.65 to 1.96)
0.89 (0.51 to 1.54)
1.05 (0.52 to 2.11)
1.11 (0.55 to 2.23)
0.55 (0.12 to 2.55)
N=43 N=140
IL-1R pst-1
1970
C
T
CC
TC
TT
58 (67.4)
28 (32.6)
20 (46.5)
18 (41.9)
5 (11.6)
174 (62.1)
106 (44.2)
54 (38.6)
66 (47.1)
20 (14.3)
0.443
0.443
0.378
0.602
0.802
1.26 (0.76 to 2.11)
0.79 (0.48 to 1.32)
1.39 (0.7 to 2.76)
0.81 (0.40 to 1.61)
0.79 (0.28 to 2.25)
N=43 N=140
IL-1RA mspa-1
11100
C
T
CC
TC
TT
18 (20.9)
68 (79.1)
2 (4.6)
14 (32.6)
27 (62.8)
64 (22.9)
216 (77.1)
4 (2.9)
56 (40)
80 (57.1)
0.769
0.769
0.627
0.474
0.597
0.89 (0.50 to 1.61)
1.12 (0.62 to 2.02)
1.66 (0.29 to 9.39)
0.72 (0.35 to 1.49)
1.27 (0.63 to 2.56)
Tab. 1. Allele and genotype frequencies in patients with ischemic heart failure and healthy controls.
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quencies for all cytokine gene polymorphisms were assessed by 
direct gene counting. Frequencies of alleles and genotypes were 
compared between the case and control groups using the Fisher’s 
exact test. The odds ratio and 95 % confi dence intervals for the 
infl uence of the aforementioned SNPs on ischemic heart failure 
risk were calculated. A p-value less than 0.05 was regarded sta-
tistically signifi cant. 
Results
Alleles and genotype frequencies
Allelic and genotype frequencies in patients with ischemic 
heart failure and healthy controls are depicted in Table 1.
We found a signifi cant positive association for IL-1β -511/C 
allele (69 % vs 55.4 %, p = 0.031) with ischemic heart failure. In 
addition, the IL-1β C/C genotype at position -511 was signifi cantly 
overrepresented in patients with ischemic heart failure compared 
to healthy controls (45.2 % vs 25.8 %, p = 0.022). 
The allele and genotype frequencies of IL-1α at position -899, 
IL-1β at position +3962, IL-1R at position psti1970 and IL-1RA 
at position mspai11100 were similar in two groups of patients 
and controls.
Discussion
In the present study an increased frequency of the IL-1β -511/C 
allele was found in patients with ischemic heart failure, whereas 
the T allele at the same position was signifi cantly decreased. 
Moreover, the frequency of the IL-1β (-511) C/C genotype was 
signifi cantly higher in our patients compared to controls. It has 
been shown that IL-1β (-511) C/C genotype is associated with in-
creased in vitro IL-1β expression of mononuclear cells in response 
to lipopolysaccharide (LPS) (24). IL-1β -511C/T polymorphism 
seems to affect the risk of myocardial infarction, as the main cause 
of systolic heart failure, at young age (24); however, neither in-
dividual SNPs nor SNP haplotypes in the promoter region of the 
IL-1β gene were signifi cantly associated with the incidence of 
acute coronary syndromes in patients above the age of 50 years 
(25). In a more recent study, IL-1β (-511) T/T genotype has been 
shown to be an independent predictor of left ventricular systolic 
dysfunction (LVSD) in patients with IHD (26). In this study, the 
production of IL-1β under stress conditions was dramatically 
less in patients with both IL-1β (-511) T/T genotype and LVSD. 
Hence, it has been postulated that, an inadequate response of IL-
1β under stress conditions in carriers of IL-1β (-511) T/T genotype 
may impair the cytoprotective effects of IL-1β on the ischemic 
myocardium (26). Our results, on the other hand, imply that the 
IL-1β (-511) C/C genotype might contribute to the development 
of ischemic heart failure. Therefore, it could be suggested that the 
apparent increase in the IL-1β (-511) C/C genotype in the patient 
group might be responsible for the high-producer phenotype, 
playing prominent roles in mediating maladaptive responses in 
the context of the failing heart (4).
Our study has certain limitations to be acknowledged. Firstly, 
the relatively small number of cases in the patient group reduces 
the statistical power, thereby not allowing for comparison among 
the groups, with regards to disease severity. Therefore, given the 
small number of patients in this study, any conclusions can only 
be interpreted with caution. Furthermore, serum level of IL-1 was 
not measured in this investigation, which results in our inability 
to evaluate the relevance of the aforementioned gene variants in 
terms of cytokine levels in patients with ischemic heart failure.
In conclusion, this study demonstrates the association between 
specifi c allele and genotype frequencies in IL-1β gene in addition 
to IL-4, which was previously showed (27), with ischemic heart 
failure. These associations may help us defi ne novel genetic pre-
disposing factors in regard to this disease. However, in order to 
delineate the role of IL-1 family genotypes in the pathogenesis of 
ischemic heart failure, further investigation using a larger sample 
size is recommended.
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